(NASDAQ: VCYT) Veracyte's forecast annual revenue growth rate of 10.33% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 61.88%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.63%.
Veracyte's revenue in 2024 is $361,051,000.On average, 4 Wall Street analysts forecast VCYT's revenue for 2024 to be $29,957,241,057, with the lowest VCYT revenue forecast at $29,861,979,989, and the highest VCYT revenue forecast at $30,077,424,641. On average, 5 Wall Street analysts forecast VCYT's revenue for 2025 to be $32,989,755,903, with the lowest VCYT revenue forecast at $31,843,770,517, and the highest VCYT revenue forecast at $33,482,501,093.
In 2026, VCYT is forecast to generate $36,029,702,463 in revenue, with the lowest revenue forecast at $36,029,702,463 and the highest revenue forecast at $36,029,702,463.